Search

everythinglearnresearchcommunity

for

Search:↓

Low-dose oral contraceptives reduced hair growth and testosterone levels in women with polycystic ovary syndrome.

5α-reductase deficiency can cause ambiguous genitalia and gender dysphoria, treatable with testosterone.

Young men's sexual dysfunction often has physical causes, which can lead to stress and worsen the problem.

SSRI antidepressants can cause long-lasting sexual problems.

Men with low testosterone should be carefully evaluated and monitored before and during treatment.

Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

Estrogen deficiency can reduce the enzyme activity needed to activate vitamin D.

The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.

A postmenopausal woman had high testosterone from her right adrenal gland, leading to recommended surgery.

5α-reductase-2 deficiency causes ambiguous genitalia at birth and affects male sexual development, but individuals often develop male characteristics at puberty.

Finasteride may help reduce inappropriate sexual behaviors in dementia patients with prostate issues.

More hair loss leads to higher risk of psychosexual disorders, especially in women.

Men with androgenetic alopecia may have more sexual dysfunctions.

Testosterone treatment for older men can have short-term benefits, but long-term risks are unclear, requiring careful evaluation and monitoring.

Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.

Low DHEA-S levels might be linked to alopecia areata and could be a potential treatment target.

Some men taking finasteride for hair loss may experience sexual problems like erectile dysfunction and decreased sex drive, which can persist even after stopping the medication.

The new oral testosterone pill normalized testosterone levels and lowered SHBG in men with low testosterone.

Antiandrogen therapy may be beneficial for women with hidradenitis suppurativa.

The transscrotal testosterone patch normalizes hormone levels in men with AIDS and weight loss but does not improve weight, body mass, or quality of life.

PFS and PSSD are similar conditions with persistent sexual dysfunction after stopping medication.

Hair loss in women linked to higher sexual dysfunction risk.

A 15-year-old girl with rare reproductive disorders received hormone therapy to develop secondary sexual traits, but infertility persisted.

5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.

Finasteride's sexual side effects not caused by androgen deficiency or SRD5A inhibition.

Women with hyperandrogenic amenorrhea have similar bone density to healthy women but lower than androgenized women without amenorrhea, and high DHEAS levels might affect bone density.

The therapies improved ejaculation disorders and sexual function in middle-aged men.